Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells
- PMID: 12704385
- DOI: 10.1038/nm869
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells
Abstract
Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs). As a result, there are only limited reports of expansion of antigen-specific CTLs to the levels required for clinical therapy. To address this issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) and CD28-specific antibody to beads. HLA-Ig-based aAPCs were used to induce and expand CTLs specific for cytomegalovirus (CMV) or melanoma. aAPC-induced cultures showed robust antigen-specific CTL expansion over successive rounds of stimulation, resulting in the generation of clinically relevant antigen-specific CTLs that recognized endogenous antigen-major histocompatibility complex complexes presented on melanoma cells. These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTLs for clinical approaches to adoptive immunotherapy.
Similar articles
-
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.Cancer Res. 2005 Jun 15;65(12):5417-27. doi: 10.1158/0008-5472.CAN-04-2991. Cancer Res. 2005. PMID: 15958591
-
Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.Cancer Lett. 2008 Nov 18;271(1):129-39. doi: 10.1016/j.canlet.2008.05.049. Epub 2008 Jul 14. Cancer Lett. 2008. PMID: 18621475
-
Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells.Transfusion. 2007 Nov;47(11):2143-52. doi: 10.1111/j.1537-2995.2007.01439.x. Transfusion. 2007. PMID: 17958544
-
HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.Clin Immunol. 2004 Mar;110(3):243-51. doi: 10.1016/j.clim.2003.11.014. Clin Immunol. 2004. PMID: 15047202 Review.
-
Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.Discov Med. 2009 Dec;8(43):210-8. Discov Med. 2009. PMID: 20040272 Review.
Cited by
-
Multimodal probing of T-cell recognition with hexapod heterostructures.Nat Methods. 2024 Feb 19. doi: 10.1038/s41592-023-02165-7. Online ahead of print. Nat Methods. 2024. PMID: 38374262
-
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.Blood Adv. 2023 Aug 8;7(15):4124-4134. doi: 10.1182/bloodadvances.2022009397. Blood Adv. 2023. PMID: 37196643 Free PMC article.
-
Shape matters: Biodegradable anisotropic nanoparticle artificial antigen presenting cells for cancer immunotherapy.Acta Biomater. 2023 Apr 1;160:187-197. doi: 10.1016/j.actbio.2023.02.023. Epub 2023 Feb 21. Acta Biomater. 2023. PMID: 36812956
-
Chemical communication at the synthetic cell/living cell interface.Commun Chem. 2021 Nov 25;4(1):161. doi: 10.1038/s42004-021-00597-w. Commun Chem. 2021. PMID: 36697795 Free PMC article. Review.
-
Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.Adv Healthc Mater. 2023 May;12(12):e2203163. doi: 10.1002/adhm.202203163. Epub 2023 Jan 31. Adv Healthc Mater. 2023. PMID: 36645182
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
